



HIGHLIGHT



Who are you?



BioAZ develops innovative immunotherapies for animal health.

Founded in 2022 by a veterinarian, the French biotech meets unmet needs in pets and livestock, with ethical and sustainable solutions that support the agroecological transition.



What is your expertise?



BioAZ develops next-generation veterinary immunotherapies based on VHHs (single-domain antibodies derived from camelid heavy-chain antibodies). Our expertise combines advanced biotech engineering with deep field insight to deliver innovative, ethical solutions for both companion animals and livestock.



What are your key products or services?

Our lead projects focus on reproductive control in animals, offering **non-invasive, ethical alternatives to surgical castration** in dogs and pigs.

We are also developing an early-stage immunotherapy as an **alternative to antibiotics** for a zoonotic disease in calves. And more breakthrough projects to come!



Can you sum up your company in 3 words?

- Immunotherapies
- Innovative
- Ethical



Contact

Information

Romain Delcombel

CEO

romain.delcombel@bioaz.vet

www.bioaz.vet